Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
Disclosed herein are methods of treating cardiac arrhythmia with electronic monitoring in a timely manner. Also disclosed herein are systems for electronic monitoring of cardiac arrhythmia.
1. A method of treating cardiac arrhythmia in a subject, comprising:
(a) identifying cardiac arrhythmia in the subject with the aid of an electronic monitoring device;
(b) aerosolizing a pharmaceutical composition in less than about 9 minutes using an inhaler, wherein the pharmaceutical composition comprises a therapeutically effective amount of at least one antiarrhythmic or a pharmaceutically acceptable salt thereof; and
(c) administering the aerosolized pharmaceutical composition to the subject; thereby treating the cardiac arrhythmia;
wherein the electronic monitoring device provides instruction for the administering the aerosolized pharmaceutical composition.
2. The method of claim 1 , wherein the identifying of (a) includes an establishing of a duration of the cardiac arrhythmia.
3. The method of claim 2 , wherein the duration of the cardiac arrhythmia is at least about 0.5 hours.
4. The method of claim 1 , wherein the therapeutically effective amount is an amount sufficient to convert the cardiac arrhythmia to normal sinus rhythm.
5. The method of claim 4 , wherein the therapeutically effective amount is at least about 30 mg of the at least one antiarrhythmic or pharmaceutically acceptable salt thereof.
6. The method of claim 4 , wherein the therapeutically effective amount converts the cardiac arrhythmia to normal sinus rhythm from about 0 secs to about 2 hours after the administration.
7. The method of claim 1 , wherein prior to (a), an electronic monitoring chip is inserted into the subject or is worn by the subject.
8. The method of claim 7 , wherein the electronic monitoring chip is in wireless communication with the electronic monitoring device.
9. The method of claim 1 , wherein prior to (a), an electronic monitoring chip is inserted into the electronic monitoring device.
10. The method of claim 1 , wherein the identifying of (a) comprises a communication of a result to the subject.
11. The method of claim 1 , wherein the identifying of (a) comprises a communication of a result to a healthcare professional.
12. The method of claim 1 , wherein the at least one antiarrhythmic or pharmaceutically acceptable salt thereof is a class I antiarrhythmic, class II antiarrhythmic, class III antiarrhythmic, class IV antiarrhythmic, class V antiarrhythmic, or a pharmaceutically acceptable salt of any of these.
13. The method of claim 1 , wherein the at least one antiarrhythmic or pharmaceutically acceptable salt thereof comprises flecainide.
14. The method of claim 1 , wherein the inhaler is in communication with the electronic monitoring device, wherein the communication is a wired communication or a wireless communication.
15. A system comprising:
a. an electronic monitoring chip; wherein the electronic monitoring chip monitors incidence of arrhythmia in a subject;
b. an electronic monitoring device; wherein the electronic monitoring device is in wireless communication with the electronic monitoring chip; and
c. an inhaler; wherein the electronic monitoring device is in communication with the inhaler.
16. The system of claim 15 , wherein the electronic monitoring device comprises a digital display.
17. The system of claim 15 , wherein the electronic monitoring device comprises auditory means capable of communicating to the subject.
18. The system of claim 15 , wherein the electronic monitoring device is a smartphone.
19. The system of claim 15 , wherein the electronic monitoring device comprises storage means.
20. The system of claim 19 , wherein subject data is stored using the storage means, and wherein the storage means is a hard drive or a cloud based storage.